149 related articles for article (PubMed ID: 38759932)
1. Design and synthesis of novel thiazole-derivatives as potent ALK5 inhibitors.
Arai M; Hanada M; Moriyama H; Ohmoto H; Miyake T; Naka K; Sawa M
Bioorg Med Chem Lett; 2024 Aug; 108():129797. PubMed ID: 38759932
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and evaluation of novel 4-thiazolylimidazoles as inhibitors of transforming growth factor-β type I receptor kinase.
Amada H; Sekiguchi Y; Ono N; Matsunaga Y; Koami T; Asanuma H; Shiozawa F; Endo M; Ikeda A; Aoki M; Fujimoto N; Wada R; Sato M
Bioorg Med Chem Lett; 2012 Mar; 22(5):2024-9. PubMed ID: 22325945
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological activity evaluation of novel 4-((1-cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl) oxy) pyridine-2-yl) amino derivatives as potent transforming growth factor-β (TGF-β) type I receptor inhibitors.
Tan B; Zhang X; Quan X; Zheng G; Li X; Zhao L; Li W; Li B
Bioorg Med Chem Lett; 2020 Aug; 30(16):127339. PubMed ID: 32631540
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and evaluation of a pyrazolo[3,4-d]pyrimidine derivative as a novel and potent TGFβ1R1 inhibitor.
Wang Y; Liu Y; Zhang Y; Zhang Z; Xu L; Wang J; Yang Y; Hu B; Yao Y; Wei M; Wang J; Tang B; Zhang K; Liu S; Yang G
Eur J Med Chem; 2024 May; 271():116395. PubMed ID: 38626523
[TBL] [Abstract][Full Text] [Related]
5. ALK5 kinase inhibitory activity and synthesis of 2,3,4-substituted 5,5-dimethyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazoles.
Řezníčková E; Tenora L; Pospíšilová P; Galeta J; Jorda R; Berka K; Majer P; Potáček M; Kryštof V
Eur J Med Chem; 2017 Feb; 127():632-642. PubMed ID: 28135685
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluation of 4-(pyridine-4-oxy)-3-(tetrahydro-2H-pyran-4-yl)-pyrazole derivatives as novel, potent of ALK5 receptor inhibitors.
Wang Z; Zhang Y; Wang H; Wang X; Yu Z; Zhao L
Bioorg Med Chem Lett; 2022 Apr; 61():128552. PubMed ID: 35051574
[TBL] [Abstract][Full Text] [Related]
7. Advances in the discovery of activin receptor-like kinase 5 (ALK5) inhibitors.
Mansour MA; Hassan GS; Serya RAT; Jaballah MY; Abouzid KAM
Bioorg Chem; 2024 Jun; 147():107332. PubMed ID: 38581966
[TBL] [Abstract][Full Text] [Related]
8. Pharmacophore modeling and virtual screening for the discovery of new transforming growth factor-beta type I receptor (ALK5) inhibitors.
Ren JX; Li LL; Zou J; Yang L; Yang JL; Yang SY
Eur J Med Chem; 2009 Nov; 44(11):4259-65. PubMed ID: 19640613
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and optimization of 7-substituted-pyrazolo[4,3-b]pyridine ALK5 (activin receptor-like kinase 5) inhibitors.
Sabat M; Wang H; Scorah N; Lawson JD; Atienza J; Kamran R; Hixon MS; Dougan DR
Bioorg Med Chem Lett; 2017 May; 27(9):1955-1961. PubMed ID: 28359790
[TBL] [Abstract][Full Text] [Related]
10. Rapid generation of a high quality lead for transforming growth factor-beta (TGF-beta) type I receptor (ALK5).
Goldberg FW; Ward RA; Powell SJ; Debreczeni JE; Norman RA; Roberts NJ; Dishington AP; Gingell HJ; Wickson KF; Roberts AL
J Med Chem; 2009 Dec; 52(23):7901-5. PubMed ID: 19736928
[TBL] [Abstract][Full Text] [Related]
11. Tgf-beta type I receptor (Alk5) kinase inhibitors in oncology.
Ling LE; Lee WC
Curr Pharm Biotechnol; 2011 Dec; 12(12):2190-202. PubMed ID: 21619541
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of 5-(pyridin-2-yl)thiazoles as transforming growth factor-beta type1 receptor kinase inhibitors.
Kim DK; Choi JH; An YJ; Lee HS
Bioorg Med Chem Lett; 2008 Mar; 18(6):2122-7. PubMed ID: 18262787
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and evaluation of small molecule imidazo[2,1-b][1,3,4]thiadiazoles as inhibitors of transforming growth factor-β type-I receptor kinase (ALK5).
Patel HM; Sing B; Bhardwaj V; Palkar M; Shaikh MS; Rane R; Alwan WS; Gadad AK; Noolvi MN; Karpoormath R
Eur J Med Chem; 2015 Mar; 93():599-613. PubMed ID: 25234355
[TBL] [Abstract][Full Text] [Related]
14. Design of novel quinazoline derivatives and related analogues as potent and selective ALK5 inhibitors.
Gellibert F; Fouchet MH; Nguyen VL; Wang R; Krysa G; de Gouville AC; Huet S; Dodic N
Bioorg Med Chem Lett; 2009 Apr; 19(8):2277-81. PubMed ID: 19285388
[TBL] [Abstract][Full Text] [Related]
15. Transforming growth factor-beta1 protects against pulmonary artery endothelial cell apoptosis via ALK5.
Lu Q
Am J Physiol Lung Cell Mol Physiol; 2008 Jul; 295(1):L123-33. PubMed ID: 18456797
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological evaluation of 1,2,4-trisubstituted imidazoles and 1,3,5-trisubstituted pyrazoles as inhibitors of transforming growth factor beta type 1 receptor (ALK5).
Li X; Wang L; Long L; Xiao J; Hu Y; Li S
Bioorg Med Chem Lett; 2009 Aug; 19(16):4868-72. PubMed ID: 19616940
[TBL] [Abstract][Full Text] [Related]
17. Discovery of N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): a highly potent, selective, and orally bioavailable inhibitor of TGF-β type I receptor kinase as cancer immunotherapeutic/antifibrotic agent.
Jin CH; Krishnaiah M; Sreenu D; Subrahmanyam VB; Rao KS; Lee HJ; Park SJ; Park HJ; Lee K; Sheen YY; Kim DK
J Med Chem; 2014 May; 57(10):4213-38. PubMed ID: 24786585
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and antifibrosis evaluation of 4-(benzo-[c][1,2,5]thiadiazol-5-yl)-3(5)-(6-methyl- pyridin-2-yl)pyrazole and 3(5)-(6-methylpyridin- 2-yl)-4-(thieno-[3,2,-c]pyridin-2-yl)pyrazole derivatives.
Zhu WJ; Cui BW; Wang HM; Nan JX; Piao HR; Lian LH; Jin CH
Eur J Med Chem; 2019 Oct; 180():15-27. PubMed ID: 31299584
[TBL] [Abstract][Full Text] [Related]
19. Screening and identification of a novel class of TGF-β type 1 receptor kinase inhibitor.
Huynh QK; Wise SJ; Koch KA; Castonguay LA; Reid BG; Pagratis EE; Koditek D; Glascock CB; Pitts KR; Turner BA; Liu X; Hung M; Han B; Pagratis N
J Biomol Screen; 2011 Aug; 16(7):724-33. PubMed ID: 21521800
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542.
Laping NJ; Grygielko E; Mathur A; Butter S; Bomberger J; Tweed C; Martin W; Fornwald J; Lehr R; Harling J; Gaster L; Callahan JF; Olson BA
Mol Pharmacol; 2002 Jul; 62(1):58-64. PubMed ID: 12065755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
